A Study to Test the Effectiveness and Safety of MK0893 in Combination With Other Drugs Used to Treat Type 2 Diabetes (0893-015)

Summary

This study will test the effectiveness and safety of treatment with MK-0893 in combination with other drugs commonly used to treat type 2 diabetes for a duration up to 13 weeks.

Timeline

Start

2008-02

Primary completion

2009-01

Completion

2009-01

Outcome

Mixed primary results

registry MK-0893 + Sitagliptin vs Sitagliptin + Metformin; p = 0.002; Mean Difference (Final Values) 13.9 (95% CI 5.2 to 22.7) NCT00631488 ↗

registry LEAST_SQUARES_MEAN MK-0893 + Sitagliptin: -85.7 (Standard Error 4.6) mg/dL NCT00631488 ↗

registry MK-0893 + Metformin vs Sitagliptin + Metformin; p <0.001; Mean Difference (Final Values) -17.8 (95% CI -26.5 to -9.2) NCT00631488 ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	MK-0893	Small molecule	40 mg	Oral
Subject	Metformin	Small molecule	1000 mg	Oral
Subject	Sitagliptin	Small molecule	100 mg	Oral

Indications